A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer

作者
Masahiro Kashiwaba,Yoshinori Ito,Shintaro Takao,Hiroyoshi Doihara,Yoshiaki Rai,Kazumitsu Kanatani,Shigemitsu Takashima,Norikazu Masuda
出处
期刊:Japanese Journal of Clinical Oncology [Oxford University Press]
卷期号:46 (5): 407-414 被引量:23
标识
DOI:10.1093/jjco/hyw013
摘要

OBJECTIVE: Trastuzumab emtansine significantly improved progression-free survival and overall survival when compared with lapatinib-capecitabine in pretreated human epidermal growth factor receptor 2-positive advanced breast cancer. However, data in Japanese populations are limited. METHODS: In the single-arm Phase II JO22997 study, Japanese patients with human epidermal growth factor receptor 2-positive inoperable locally advanced/recurrent or metastatic breast cancer previously treated with at least one prior chemotherapy regimen for locally advanced/recurrent or metastatic breast cancer and trastuzumab in any setting received 3.6 mg/kg trastuzumab emtansine every 3 weeks until progression, unacceptable toxicity or consent withdrawal. The primary endpoint was Independent Review Committee-assessed objective response rate. Secondary endpoints included progression-free survival, overall survival, safety and pharmacokinetics. RESULTS: The objective response rate in 73 treated patients was 38.4% (90% confidence interval, 28.8-48.6%), exceeding the prespecified boundary for an objective response rate > 20%. After 6.5 months' median follow-up, median progression-free survival was 5.6 months (95% confidence interval, 4.6-8.2). After 28.9 months' median follow-up, median overall survival was 30.5 months (95% confidence interval 25.2-not reached). There were no treatment-related deaths. The most common Grade 3/4 adverse events were thrombocytopenia (22%) and aspartate aminotransferase elevations (14%). Thrombocytopenia did not require platelet transfusion and typically recovered before the next cycle. There were no substantial differences in trastuzumab emtansine or trastuzumab pharmacokinetic parameters between this study and previous data from non-Japanese patients. CONCLUSIONS: JO22997 results suggest high activity of trastuzumab emtansine in Japanese patients, a safety profile consistent with previous studies in non-Japanese patients, no new safety signals and no evidence of pharmacokinetic differences between Japanese and non-Japanese populations. These results support trastuzumab emtansine therapy for Japanese patients with chemotherapy- and trastuzumab-pretreated human epidermal growth factor receptor 2-positive locally advanced/recurrent or metastatic breast cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
南风知我意完成签到,获得积分10
刚刚
xxxpeacey发布了新的文献求助10
1秒前
金光闪闪完成签到,获得积分10
2秒前
kk发布了新的文献求助10
3秒前
ni发布了新的文献求助10
4秒前
YANG11完成签到,获得积分10
4秒前
5秒前
5秒前
我是老大的应助被无辜的翠安采纳,获得10
5秒前
5秒前
5秒前
卫生五蚕体完成签到,获得积分10
6秒前
阿东发布了新的文献求助10
7秒前
7秒前
西陆发布了新的文献求助10
8秒前
秋风的应助被霍紫菡采纳,获得10
8秒前
NexusExplorer的应助被Cc采纳,获得10
9秒前
nixay621发布了新的文献求助10
9秒前
小航发布了新的文献求助10
10秒前
hsl完成签到 ,获得积分10
10秒前
三分之二发布了新的文献求助10
11秒前
陈攀完成签到,获得积分10
11秒前
苗条故事发布了新的文献求助10
11秒前
136586完成签到 ,获得积分10
11秒前
12秒前
wznx完成签到,获得积分10
13秒前
Jasper的应助被怀夕采纳,获得10
13秒前
13秒前
会发光的喷火龙完成签到,获得积分10
15秒前
L1完成签到,获得积分10
15秒前
16秒前
神奇的大蛇丸完成签到,获得积分10
16秒前
桐桐的应助被快乐是无敌采纳,获得10
16秒前
踏实尔阳完成签到,获得积分10
16秒前
叶子发布了新的文献求助10
16秒前
灼灼朗朗完成签到,获得积分10
17秒前
王帅松完成签到,获得积分10
17秒前
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177767
求助须知:如何正确求助?哪些是违规求助? 9568590
关于积分的说明 21799821
捐赠科研通 7772374
什么是DOI,文献DOI怎么找? 3432476
关于科研通互助平台的介绍 2556695
邀请新用户注册赠送积分活动 2478034